GMJ Technologies, a Seattle-based life sciences tools company, announced the appointment of Carol Berry as Chief Executive Officer, effective June 1, 2026, according to a statement issued on June 9. Berry, who brings more than 30 years of experience in life sciences and biotech, succeeds founder Tosin Dada, who remains as President and Chief Technology Officer in what represents a common transition at technology-driven startups seeking commercial leadership. The appointment underscores GMJ's shift toward scaling a proprietary analytical platform designed to simplify protein characterization for biopharmaceutical companies.
Berry was most recently Senior Vice President and Chief Business Officer of CellCarta, formerly known as Caprion Bioscience, where she spent nine years consistently delivering double-digit revenue growth while establishing the firm as a leader in specialty contract research laboratories. Prior to that role, she served as Senior Vice President and General Manager of the genomics services division at Asuragen, a molecular diagnostics company. Her earlier career included multiple positions in sales and marketing at clinical diagnostics and biomarker discovery firms. Berry holds a Bachelor of Science from Texas A&M University and an MBA in Information Technology Management from the University of Dallas. In her new role, she will oversee strategy, investor relations, funding initiatives, partnerships, market expansion, and regulatory compliance. Dada said in a statement that Berry brings "a strong track record of leadership and a clear passion for innovation."
Berry's appointment reflects her deep expertise in commercializing laboratory-based life science tools, a sector increasingly vital to the biopharmaceutical industry. She also serves on the board of InterVenn Biosciences, a clinical technology company leveraging glycoproteomics. Her appointment comes after she was recognized as a "Woman Who Inspires" by the State of California. Additionally, she previously served as founding CEO and President of Immunexpress Global Group in Seattle from 2006 to 2017, where she managed development, FDA regulatory clearance, and commercialization of SeptiCyte, a Medtech Innovation award-winning medical diagnostic technology, while raising over 40 million dollars in capital.
GMJ Technologies, founded in 2018 by Dada, spun out of the University of Washington and operates as a privately held company with fewer than 10 employees. The firm develops analytical solutions centered on a proprietary capillary electrophoresis platform integrated with optical-electrospray ionization mass spectrometry, branded as the CeMAX UV system. The technology targets bottlenecks in protein analysis across drug development, quality assurance, and proteomics research. GMJ offers both early access programs and contract services enabling customers to characterize protein samples with minimal volumes and rapid turnaround. The company benefits from experienced advisory support, including Paul Latta, who brings 25 years of investment banking and venture capital experience, and Ken Marzinsky, a serial startup executive.
The appointment reflects industry momentum in analytical instrumentation, particularly in protein characterization. The capillary electrophoresis market was valued at approximately 370 million dollars in 2024 and is projected to reach 507 million dollars by 2030, according to market research. Protein analysis applications are anticipated to grow at the fastest rate, driven by the increasing demand for detailed characterization of therapeutic biologics. By recruiting Berry, GMJ acquires seasoned commercial expertise at a critical juncture as it likely prepares to accelerate commercialization of its CeMAX platform. Her track record scaling specialty contract research operations suggests the company may be considering expanded service offerings alongside instrument sales, a common strategy in the analytical instruments sector. The shift of founder Dada toward technical leadership while maintaining strategic involvement is typical in biotech, allowing technical innovators to focus on product advancement while external executives drive market penetration and investor relations.
